Zosano Pharma Corp (ZSAN): M James Barrett , 10% owner of Zosano Pharma Corp sold 13,382 shares on Jul 13, 2016. The Insider selling transaction was reported by the company on Jul 15, 2016 to the Securities and Exchange Commission. The shares were sold at $1.20 per share for a total value of $16,059.74 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Feb 2, 2015, M James Barrett (director 10% owner) purchased 23,457 shares at $11.00 per share price.
Shares of Zosano Pharma Corp (ZSAN) ended Friday, Jul 15, 2016 session in red amid volatile trading. The shares closed down -0.02 points or -1.72% at $1.14 with 17,370 shares getting traded. Post opening the session at $1.16, the shares hit an intraday low of $1.11 and an intraday high of $1.18 and the price vacillated in this range throughout the day. The company has a market cap of $14 M and the number of outstanding shares has been calculated to be 1,20,12,548 shares. The 52-week high of Zosano Pharma Corp is $9.5 and the 52-week low is $1.03.
Zosano Pharma Corporation is a clinical-stage specialty pharmaceutical company. The company has developed a transdermal microneedle patch system to deliver its formulations of existing drugs through the skin for the treatment of a range of indications. Its microneedle patch system offers rapid onset consistent drug delivery and improved ease of use and room-temperature stability. Its microneedle patch system has the potential to deliver numerous medications for a range of indications in commercially attractive markets. The Company’s short-wear-time transdermal patch consists of an array of titanium microneedles that is coated with its formulation of an existing drug and attached to an adhesive patch. Its lead product candidates and the indications they are expected to treat include Daily ZP-PTH for severe osteoporosis; ZP-Glucagon for severe hypoglycemia and ZP-Triptan for migraine.